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Abstract
Background: Cardiovascular diseases are the major cause of death in Bulgaria. Because of notable
differences in mortality rates between Bulgaria and other European countries, we presume a
tangible difference in the management of acute myocardial infarction (AMI) and an underutilization
of evidence-based treatments. In order to determine the quality of care of patients with AMI in
Bulgaria, we analyzed the appropriateness of current treatments and their relation to patient
characteristics.
Methods: We performed a descriptive cross-sectional study, using retrospectively collected data
from medical charts. We included all patients with AMI, residing and admitted to hospitals in the
region of Stara Zagora, Bulgaria, between September 1st and December 31st, 2004. Socioeconomic
status was surveyed within the framework of a structured patient interview. We used chi-square
tests with Fisher's exact probabilities to analyze the relationship between prehospital time delay
age, sex, and socio-economic status of the patients and Student's independent samples t-tests to
check hypotheses about means.
Results: From 134 patients with AMI (mean age 64.6, SD 13.2, 66% male), 7% presented to a
hospital within 59 minutes, and 44% within 4 hours of symptoms onset. The use of Heparin was
98%. In the first 24 hours, ASS was administrated in 82% and β-Blockers in 73% of the cases. At
discharge Aspirin, β-Blockers, Angiotensin Converting Enzyme Inhibitors or AR-Blockers and
Statins were used in 85%, 79%, 66%, and 43% of cases respectively. Intravenous fibrinolysis was
applied in 32% of the eligible patients with ST-segment elevation. Percutaneous coronary
interventions were applied in four patients within the first month after AMI. Hospital location in
relation to a patient's place of residence and manner of transportation to hospital did not influence
the time delay between the onset of symptoms to the start of hospital treatment. In the study
region, a relation between time delay and both age and education level was observed.
Conclusion: The actual quality of care of patients with AMI in Bulgaria lies far from the evidence-
based recommendations. Additional research and improvements in health services are needed to
reduce the burden of cardiovascular disease in Bulgaria.
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Background
As in many parts of the world, cardiovascular diseases
(CVD) are the main cause of death and disability in Bul-
garia. CVD were responsible for 61.5% of all deaths in
Bulgaria in 1990, and for 67.5% of all deaths in 2004
[1,2]. In 2004, 16.7% of all deaths were caused by ischae-
mic heart diseases (IHD) and 6.4% by acute myocardial
infarction (AMI).
Considering the CVD mortality rates in Bulgaria, one of
the goals of the health care reforms that replaced the old
soviet-style system in Bulgaria was to decrease CVD mor-
tality by implementing evidence-based diagnostic and
treatment methods.
During the past 20 years, intravenous fibrinolytic therapy
and/or percutaneous coronary intervention (PCI) were
introduced as main options for managing AMI, improving
mortality rates and reducing recurrent myocardial infarc-
tions [3-6]. PCI may be applied for more advanced stages
of AMI, and the application of fibrinolytic therapy in ST-
segment elevated myocardial infarction (STEMI) and the
benefits thereof are directly associated to the time elapsed
from the onset of the first symptoms to the beginning of
treatment [3,4,6].
However, some recent international studies indicate that
gaps exist between the guidelines of the American College
of Cardiology/American Heart Association and the actu-
ally performed in-hospital management of acute coronary
syndrome (ACS) [7,8].
In order to evaluate the quality of care of ACS patients in
Bulgaria, we compared the actual management of AMI
patients in a Bulgarian region to internationally accepted
evidence-based standards. As main factors which could
influence the mortality rates of IHD and AMI we investi-
gated the timing as well as the currently performed treat-
ment approaches of AMI inpatients.
Methods
Study region
The survey was carried out in the Stara Zagora region,
which is typical for Bulgaria in its demographic (age, sex
and urban/rural distribution) and health care characteris-
tics. The region includes nearly 5% (362,100 inhabitants)
of the total Bulgarian population of about 7.8 million
[9,10].
In-hospital care of patients with AMI is provided in six
hospitals of the region. All of them have intensive care
units and full-time residents in internal medicine. Five
hospitals have full-time residents in cardiology as well.
PCI facilities are not available in any of the hospitals in
the Stara Zagora region.
In general, the pre-hospital emergency services in Bulgaria
are provided by emergency medical facilities (EMF). The
EMFs are located in every regional centre as well as in the
bigger municipality centres. They provide emergency serv-
ices (EMS) such as check-ups, medication of symptoms,
resuscitation and, in accordance to their judgment, trans-
portation to hospitals. Bulgarian general practitioners
(GP) supply EMS to patients on their lists on rare occa-
sions. In some cases, either because of the impossibility of
receiving medical care outside the hospital or because of
the severity of a patient's condition, the patient is trans-
ported with a private carrier to hospital without any pre-
hospital investigation.
In the region of Stara Zagora, EMS are provided by three
EMF, one in the regional centre and two in the municipal-
ity centres.
Study population
During the period from September 1st to December 31st
of 2004, all inpatients residing in the region who were
admitted and treated at any of the six hospitals of the
region with the discharge diagnosis AMI (STEMI and
NSTEMI), (ICD-IX 401.0-.9) were included in the study.
The criteria used in Bulgarian hospitals for the discharge
diagnosis of AMI are as follows [11]:
1. STEMI: ischaemic symptoms lasting ≥ 20 min, cardiac
marker evidence of myocardial necrosis (positive CK-MB
and other markers) and new (or presumably new if no
prior electrocardiography (ECG) is available) ST-segment
elevation.
2. NSTEMI: cardiac marker evidence of myocardial necro-
sis (positive CK-MB or troponin) without new ST-segment
elevation.
Consent for participation in the study was obtained from
hospital boards of managers and from each patient or
patient's relatives. Since there are no ethics committees in
Bulgaria, the study was approved by the Ministry of
Health for its accordance to ethical standards.
Data from inpatient records
One physician extracted the data from inpatient medical
records following patient discharge in a structured data
collection form. A second physician performed a review of
a random sample of 20% of the records from each hospi-
tal. Consistency between the two data sets was 98%. Data
entry to a computer database was performed by a quali-
fied person. A second data entry was performed, using a
control program warning of data differences.BMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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Pre-hospital time delay
The data for calculating the pre-hospital delay of time
were extracted from the patients' charts. The pain-to-door
time was categorized into six time intervals – up to 0:59 h,
from 1:00 up to 1:59 h, from 2:00 up to 3:59 h, from 4:00
up to 11:59 h, from 12:00 up to 23:59 h and 24 h and
more. Two patient groups were considered separately in
the analysis: patients who presented to a hospital within
their area of residence formed one group, while patients
who presented to a hospital outside of their area of resi-
dence formed a second group. If a patient was transferred
from one hospital to another within the same region, only
the time of the first hospitalization was considered.
Medical history
Reviewing the medical records, we also abstracted infor-
mation about medical history of previous myocardial inf-
arction (MI), angina pectoris (AP), strokes and co-
morbidity (hypertension, diabetes mellitus and dyslipi-
demia). Data concerning family history, smoking habits
and BMI were missing in more than 40% of the medical
records and were therefore not included in the study.
In-hospital data
ECG findings, treatment approaches and specific con-
traindications, complications, length of stay (LOS) and
in-hospital outcomes were collected from inpatient
records.
The specific contraindications for administered medication,
clinically documented in the patient's medical record,
were defined as follows: for the use of Aspirin: intoler-
ance, allergy, active bleeding, a history of gastrointestinal
or genitourinary bleeding, ulcers, dyspepsia, a platelet
count of <100,000/mm3, anaemia, use of other anticoag-
ulants; for β-Blockers: allergy, hypersensitivity, bradycar-
dia, AV-block greater than I° degree, cardiogenic shock,
hypotension, chronic obstructive pulmonary disease,
asthma or bronchospasm; for Heparin: active or recent
bleeding, a platelet count of <100,000/mm3, ulcers or
serious gastrointestinal or genitourinary bleeding, a his-
tory of known heparin-induced thrombocytopenia, severe
co-morbidities; for lipid-lowering drugs: allergy, hyper-
sensitivity, hepatic or renal dysfunction, abnormal liver
function test results, primary biliary cirrhosis; for ACE
Inhibitors: allergy, intolerance, hypersensitivity, impaired
renal function, hypotension, hyperkalemia or liver dis-
ease.
Absolute contraindications for fibrinolysis therapy in
patients with acute STEMI were defined as follows: any
prior cerebral haemorrhage; known structural central
nervous system lesion (AV malformation, tumor, etc.);
ischemic stroke within 3 months except acute ischemic
stroke within 3 hours; significant head trauma within 3
months; suspected aortic dissection; active bleeding or
bleeding diathesis (excluding menses). Relative contrain-
dications were: history of chronic, severe, poorly control-
led hypertension; severe uncontrolled hypertension on
presentation (SBP greater than 180 mm Hg or DBP greater
than 110 mmHg); traumatic or prolonged cardiopulmo-
nary resuscitation (greater than 10 minutes) or major sur-
gery (less than 3 weeks); major surgery or internal
bleeding within 3–4 weeks; active peptic ulcer disease;
pregnancy; current use of anticoagulants; prior exposure
(more than 5 days ago) or prior allergic reaction to the
fibrinolytic agents.
The complications during hospital admission were defined
as: the occurrence of a new AV-Block II° or III° degree or
bundle branch block (BBB), left ventricular insufficiency,
ventricular tachycardia or cardiopulmonary resuscitation
with or without ventilation.
Socioeconomic status (SES)
The SES of the study population was surveyed within the
framework of a structured patient interview and took
place 14 to 28 days after discharge. The SES includes: 1)
education level, coded as none, primary, secondary and
college or higher education, 2) employment status, coded
as employed, unemployed or pensioner; 3) personal
monthly income, divided into four groups according to
the income levels in Bulgaria; 4) marital status, coded as
married or living with partner and single; 5) number of
family members, divided into four groups from one fam-
ily member up to four and more members (Table 1).
The interviewers were trained at the National Centre of
Public Opinion. We selected as interviewers local resi-
dents from the Stara Zagora region who were not
employed in medical institutions. For the specific aim of
the study, the interviewers received additional training.
Statistical analysis
For data description, we used tables of absolute and rela-
tive frequencies for nominal (non-metric) data and mean
values and standard deviations (SD) for continuous (met-
ric) data. The chi-square test with Fisher's exact probabili-
ties was used to test the hypothesis on the relation
between pre-hospital time delay (grouped in five intervals
– up to 0:59 minutes, from 1 up to 1:59 h, from 2 up to
3:59 h, from 4 to 11:59 hours and from 12 to 23:59 h) ver-
sus age, sex, education, and personal monthly income.
Student's independent samples t-test was applied to check
hypotheses about means. Statistical package SPSS/PC® was
used for all analyses.BMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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Results
Study population
Included in the study were a total of 134 patients with
AMI (mean age 67 ± 13.2 years), including 82 (61.2%)
with STEMI and 52 (38.8%) with NSTEMI, who were con-
secutively admitted to in-hospital treatment in the study
region (Table 1). The age range of the total population lay
between 26 and 90 years. The median age was 62 (mean
61.9 ± 13.7) years for men and 71 (mean 69.9 ± 10.2)
years for women. From the discharged patients, five
refused to participate in the interviews and one patient
died in the first days after discharge. Thus, we could not
determine their SES. Table 1 depicts the baseline charac-
teristics of the study population.
In all patients, an ECG and CK-MB examinations were
performed. Additionally, in 43 cases (32.1% of the total
population), troponin I was investigated. The complica-
tions during hospital treatment are presented in Table 2.
Cardiopulmonary resuscitation with or without ventila-
tion was performed in 16 subjects (12%). Heart insuffi-
ciency was noted in the records of 51 subjects. Ejection
fractions (EF) of < 55% were computed in 40 of them.
Pre-hospital time delay
For patients who presented to the hospital showing clini-
cal signs as well as laboratory and ECG indicators of MI
and a symptom onset of > 24 hours ago, the medical
records concerning symptom onset were often inaccurate
and mostly stated the time of symptom onset as "1–2 days
ago" or "a few days ago". Since exact time-related data for
these patients was insufficient, the median time delay for
the whole study population could not be determined. The
calculations presented include only inpatients admitted
within the first 24 hours from symptoms onset.
Table 3 presents the time interval "pain to door" accord-
ing to the patients' place of residence and the hospital
location. 66% (N = 88) of the patients were admitted to a
hospital in their area of residence and 34% (N = 46) to
hospitals outside their area of residence. For all inpatients,
STEMI and NSTEMI, the median time was 3:15 hours. For
STEMI inpatients, the median time was 3:00 hours (mean
4:32 ± 4:25 h).
The subgroup of 17 STEMI patients treated with fibrinol-
ysis was admitted for inpatient treatment within a median
of 2:00 hours (mean 2:12 ± 1:24 h). Only three of them
(18%) were admitted within 59 minutes from infarction
onset, and eight within the first 120 min. In the first 4
"golden hours", 15 patients (88% of the patients treated
Table 1: Study population – basic characteristics
Basic characteristics N (%/SD)
Gender
male 89 (66%)
female 45 (34%)
Age groups
26 – 64 years 60 (45%)
≥65 years 74 (55%)
Education
primary school or less 58 (49%)
secondary school 46 (39%)
college or high school 14 (12%)
Employment status
unemployed 98 (83%)
employed 20 (17%)
Personal monthly income
≤ 100 BGN* 33 (30%)
100.1 – 200 BGN 57 (52%)
200.1 – 300 BGN 14 (13%)
≥ 300.0 BGN 4 (4%)
unemployed without unemployment benefits 1 (1%)
Marital status
married/partner 74 (63%)
single 44 (37%)
Family members
1 member 28 (24%)
2 members 54 (46%)
3 members 14 (12%)
4 or more members 22 (19%)
History of:
Angina pectoris 78 (58%)
Previous MI 29 (22%)
MI in year 2004 6 (21%)
Stroke 15 (11%)
Hypertension 99 (74%)
Diabetes 32 (24%)
Hypercholesterolemia 11 (8%)
STEMI 82 (61%)
Gender
male 52 (63%)
female 30 (37%)
Age
median age in years 62.5
mean age in years 62.0 (12.3)
mean age male 58.7 (12.5)
mean age female 66.0 (9.8)
* Bulgarian currency Lev (BGN); 1 BGN = 0.511 €/0.68 US $
Table 2: Hospital complications
Complications N (%)
New AV-block II° and III° degree 11 (8%)
New BBB 3 (2%)
Left ventricular insufficiency 51 (38%)
Ventricular tachycardia 11 (8%)
Shock with resuscitation and/or ventilation 16 (12%)BMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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with fibrinolysis) were admitted to the hospital. The
remaining two patients had a pain-to-door time between
4 and 12 hours.
A total of 103 subjects (77%) arrived at the hospital with
an ambulance and one patient was transferred from
another health care facility.
The chi-square test with Fisher's exact probabilities was
applied for patients admitted to hospital within the first
24 hours of symptom onset. The analysis did not demon-
strate a statistically relevant relation of hospital location
and patient residence (community centre with hospital,
community centre without hospital or village) or of the
manner of transportation (with ambulance or private
vehicle) to pre-hospital time-delay (p > 0.05). We found a
statistically significant relation between pre-hospital time
delay and age as well as education level. Patients aged ≤ 64
years and subjects with higher education (college or high
school) arrived at hospital significantly later (see Table 4).
Table 3: Time-delay according to patients' domicile, hospital 
location and type of MI
Time-delay "pain to door" Hospital location/Residence
N equal N outside N (%)
up to 0:59 h 6 3 9 (7%)
STEMI patients 3 3 6
1 to 1:59 h 11 4 15 (11%)
STEMI patients 9 1 10
2 to 3:59 h 22 13 35 (26%)
STEMI patients 13 8 21
4 to 11:59 h 22 14 36 (27%)
STEMI patients 12 8 20
12 to 23:59 h 6 1 7 (5%)
STEMI patients 5 1 6
>24 h 21 11 32 (24%)
STEMI patients 12 7 19
Total 88 46 134 (100%)
STEMI patients 54 28 82 (61%)
Table 4: Relation between patients socio-demographic characteristics* and time-delay, and means, standard errors and p-values of 
differences for the statistical significant relations
Variables df** Chi-square value Exact probability
Gender 4 0.76 0.9601
Age 4 9.67 0.0348***
Education level 12 56.29 0.0029***
Personal monthly income 16 16.04 0.4503
Time delay (in hours)
Mean Standard error of mean p-value for difference
Age
≤ 64 5.83 0.71
0.005***
≥ 65 3.47 0.37
Education level
low 3.67 0.44
0.024***
high 5.45 0.64
* Patients with pain-to-door time > 24 h and patients transferred from other hospitals are excluded
** df – degree of freedom
*** the relation is statistically significantBMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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Treatment with Heparin
Heparinization in the acute care period was performed in
119 cases, thus the frequency of Heparin administration
was 98.3%. Contraindications were registered in 7
patients' records, and in the records of another 6 subjects
data concerning contraindications for Heparin treatment
was missing.
In-hospital medical treatment within the first 24 hours and 
at discharge
The medication in the first 24 hours and at discharge is
depicted in Table 5. In the first 24 hours ASS was pre-
scribed in 82% and β-Blockers in 73% of the eligible
cases. At discharge ASS was prescribed in 85% of cases, β-
Blockers in 79%, ACE-Inhibitors or AR-Blockers in 66%
and lipid-lowering drugs in 43%.
Contraindications for ASS were registered in 12 patients,
for β-Blockers in 25, for ACE-Inhibitors or AR-Blockers in
6 and for lipid-lowering drugs in 4 patients.
At admission slightly more women were medicated with
ASS and β-Blockers than men. ASS was more often pre-
scribed in patients in the age group ≥ 65. At discharge
more women received β-Blockers, ACE-Inhibitors or AR-
Blockers and lipid-lowering drugs than men. More
patients in the age group ≥ 65 years received a discharge
medication with ASS and β-Blockers.
PCI
In our sample, only four patients were transferred for
invasive investigation within the first seven to nine days.
Another two patients received PCI in the first month after
AMI. Altogether, interventional treatment was performed
in six cases within one month after AMI.
Fibrinolytic treatment
For the study period, 82 patients (61% of the study popu-
lation) were treated with the main diagnosis STEMI. 57
(69.5%) of them (34 men and 23 women) were admitted
to a hospital within the first 12 hours from symptoms
onset (see Table 3). In the medical record of one man,
contraindications for conducting fibrinolytic treatment
were noted. One man and two women were admitted
with cardiac shock and died away within a short time after
admission. According to the information obtained from
the inpatient charts, 53 subjects (32 men and 21 women)
were eligible for fibrinolytic treatment. Fibrinolytic reper-
fusion therapy with Alteplase was performed in 32% (N =
17). Lysis was applied mainly in men (N = 13; 41% of the
eligible male population). Only 19% of the eligible
women received this treatment. 53% of the patients were
< 65 years old.
In-hospital and early post-discharge mortality
10 out of the sample of 134 patients died during inpatient
treatment (7.5%), with male mortality being 3.4% (N =
3), and female mortality being 15.6% (N = 7). Nine of the
Table 5: In-hospital medical treatment in first 24 hours and at discharge*
95% CI**
Drugs N (%) Lower (%) Upper (%) Males (total %) Females (total %) % of patients
≤ 65 yrs
% of patients
≥ 65 yrs
≤ 24 hours***
ASS 92 (82%) 70.7 86.8 82% 83% 77% 87%
β-Blockers 72 (73%) 63.1 80.8 72% 75% 71% 74%
at discharge
ASS 95 (85%) 78.5 91.4 84% 86% 79% 90%
β-Blockers 99 (79%) 65.6 82.4 75% 88% 73% 85%
ACE Inhibitors/AR Blockers 78 (66%) 57.6 74.6 62% 75% 64% 68%
Lipid-lowering drugs 52 (43%) 34.4 52.2 35% 54% 47% 40%
* Patients with contraindications and missing values are excluded
** CI – confidential interval
*** Figure excludes patients who died during hospitalisationBMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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deceased patients were > 65 years of age. Within 14 days,
one more patient died at home.
Length of stay (LOS)
The median LOS was 8 days (mean 8.5, SD ± 3.3) for the
total population. For males, the median LOS was 9 days
(SD ± 3.4) and for females 7.6 days (SD ± 2.9). The LOS
of the fibrinolysis group did not differ from the total pop-
ulation with a median of 8 days (mean 8.7, SD ± 3.3). The
mean LOS according to age was 8.8 days (SD ± 3.1) for
patients aged 26 to 64 years and 8.35 days (SD ± 3.4) for
patients ≥ 65 years.
Discussion
Our study shows that most patients with AMI treated in
the Stara Zagora region in Bulgaria accessed hospital treat-
ment with a time delay and did not receive the full extent
of internationally recommended treatment. Within our
study group, patient characteristics did not influence
length of stay in the hospital.
Population
The ratio NSTEMI:STEMI (1:1.58) and female:male
(1:1.98) in our study population complies with the results
of a survey conducted in 2001–2003 in another Bulgarian
region – the Sofia district [12]. The male-female patient
ratio is close to that of other European countries [13,14].
The medical histories, considering MI and AP in the past,
as the distribution of co-morbidities (hypertension and
diabetes) in the study region correspond in terms of fre-
quency to those of other regions of the country [12].
Pre-hospital time delay
It is obvious that "pain to door" time for AMI in the Stara
Zagora Region, as measured by our study, is longer com-
pared to a number of international multicenter trials [13].
A time-trend analysis of this subject is not possible, as no
previous data has been published for the region of Stara
Zagora.
In contrast to previously reported studies [15,16], in the
region of Stara Zagora an age ≤ 64 years or higher educa-
tion levels (college or high school) were associated with a
significantly longer pre-hospital time delay (see Table 4).
Explanations for these findings might be the insufficient
training of the emergency-care staff concerning ischaemic
heart attacks in younger subjects, insufficient medical
knowledge of the public and mistrust in the health care
system especially in higher educated patients.
The fact that we could not establish a significant relation
between pre-hospital time delay and distance between
hospital location and patient's residence as well as man-
ner of arrival to hospital backs the assumption that pre-
hospital time delay could be determined by factors related
to the health care system itself:
First of all, the public in general is not sufficiently
informed about the initial symptoms of MI. Although
many people do know that chest pain is a presenting
symptom of MI, they are uninformed about associated
symptoms such as pain in the arm, pain of the lower jaw,
shortness of breath, nausea, etc., and are unaware of the
fact that it is necessary to seek medical assistance within
the first 20–30 minutes. The latter was confirmed by one
of the results of our interview study showing that 60% of
the patients self-evaluated their hospital admittance as
being within an optimal time interval [17].
Secondly, the Bulgarian population's negative opinion of
the health care system combined with the fact that admit-
tance to a hospital has become very complicated in recent
years resulted in inhabitants of smaller villages in particu-
lar preferring to wait out the symptoms at home or go to
their physician in his or her consultation hours, which
may be after two or three days. As telephone communica-
tion in the region of Stara Zagora is good, over 80% of the
inhabitants have a telephone in their home. Conse-
quently, calling the emergency services should not be a
problem for most of the population. However, it is not
always ensured that a call also elicits a response.
Treatment with Heparin
During the acute care period, heparinization was per-
formed in 98.3% of the cases. Compared with data from
the Global Registry of Acute Coronary Events (GRACE)
[18], the rate is relatively higher (98% for the Stara Zagora
region versus 86.0% for the GRACE population). A possi-
ble explanation of this finding could be the limited possi-
bilities for PCI treatment as well as for fibrinolysis.
In-hospital medical treatment within the first 24 hours and 
at discharge
Optimal conservative therapy of AMI includes at least the
use of β-Blockers and ASS, the use of Angiotensin-Con-
verting Enzyme ACE-Inhibitors as well as cholesterol sta-
tus assessment and management with lipid-lowering
drugs [19].
Administration rates for in-hospital medical treatment
during the first 24 hours from the Stara Zagora region for
ASS are similar to, and for β-Blockers higher than the fig-
ures reported by Jencks et al. [20] from the USA. Rates for
both ASS and β-Blockers are lower than those reported
from western European countries (93.8% for ASS) [14] as
well as those from the GRACE population (98.4% for ASS
and 80% for β-Blockers) [18]. During their hospitaliza-
tion, patients in the age group ≤ 65 years were less likely
to receive ASS and β-Blockers than the patients in theBMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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same age group from the CRUSADE study (77% versus
93% for ASS and 71% versus 80% for β-Blockers) [8].
Our study shows the use of conservative medication at
discharge in patients with AMI being close to the figures
reported by Jencks et al. [20] for ASS, higher for β-Blockers
and lower for ACE-inhibitors. A comparison with data
from western European countries shows that the adminis-
tration rates for the same drugs in the Stara Zagora region
are lower (91% for ASS, 80.5% for β-Blockers and 79.5%
for ACE-Inhibitors) [14]. The use of lipid-lowering drugs
at discharge from Bulgarian hospitals is also lower than
the figures from the Euro Heart Survey of ACS [21]. In
contrast to findings from other studies [22,8], the women
and older patients from the Stara Zagora region were more
likely to receive ASS, β-Blockers and ACE-Inhibitors or AR-
Blockers. The use of lipid-lowering drugs was somewhat
higher in women and patients ≤ 65 years of age.
Fibrinolytic treatment
In the Stara Zagora region, fibrinolysis under hospital
conditions can be performed in five of the six hospitals.
One of the reasons for the limited application of fibrino-
lytic reperfusion, hospital admission delay, has already
been discussed.
Another reason may be associated with hospital funding
in Bulgaria. In 2004, the National Health Insurance Fund
(NHIF) reimbursed € 1,175 for "ACS with persistent ST-
elevation and fibrinolysis", which includes only Alteplase
or Reteplase applications [11]. The estimated price at
which hospitals may have bought the most commonly
marketed drug Alteplase was € 870 for the course of one
treatment. From the reimbursement amount (€1,175),
40% (€ 470) are used for personnel remuneration. Thus,
a mere € 705 remains for laboratory and instrumental
diagnostics, lytic treatment, other medication, board and
lodging. Reteplase, which is more expensive at € 1,023, is
rarely used in Bulgaria. As a consequence of deficient
financing, physicians face limitations in decision-making
and fibrinolysis in ACS with persistent ST-elevation is
applied relatively rarely and depends more on the hospi-
tal's actual budget situation than on patients' medical
needs.
Reperfusion with Streptokinase (SK), which was applied
in Bulgaria until 2001 is not reimbursed by the NHIF.
Despite the fact that SK-administration could be associ-
ated with a rapid rise in neutralizing antibodies, making
repeated administration impractical [3,23,24], the treat-
ment with SK is associated with a lower risk for non-cere-
bral and cerebral bleeding complications compared to
Alteplase [25]. Besides, SK is significantly cheaper [3]. In
Bulgaria, the price of 1.5 million units of SK (the common
fibrinolysis dose) is about € 164.0.
According to up-to-date evidence, the implementation of
pre-hospital intravenous fibrinolytic reperfusion therapy
should be considered when the time needed to reach an
inpatient health care facility is estimated to exceed 60
minutes [26]. Unfortunately, in the region of Stara
Zagora, the initiation of treatment under outpatient con-
ditions does not take place for a number of reasons – lack
of thrombolytic drugs, lack of training and poor condi-
tions during transportation.
PCI
In Bulgaria and in the Stara Zagora region in particular,
PCI facilities are very limited. Although ischaemic heart
disease represents one of the most common reasons for
death in Bulgaria, the health care system does not provide
the facilities to perform the adequate number of invasive
interventions. The medical facilities in Bulgaria are able to
provide 254 invasive investigations and 124 interven-
tional treatment procedures per one million inhabitants
per year. Considerable investments in equipment, tech-
nology and training are necessary in order to meet the
population's needs. For this reason, the fibrinolytic reper-
fusion therapy represents the most common reperfusion
strategy for the medical management of STEMI in Bulgaria
and in the Stara Zagora region.
Mortality
The mortality rate at Stara Zagora hospitals is similar to
the figures of the GRACE trial [18], as well as data of other
surveys [7]. The gender distribution shows female mortal-
ity being somewhat higher than male mortality. The com-
mon ratio is about 2:1 [27], which corresponds to the data
of another Bulgarian region [12].
In our study, the average age of the deceased women was
72.6 years versus 76.3 for men. Four of the females were
admitted within the first two hours after symptoms onset
versus one man admitted in the same time interval. Only
two women did not need resuscitation and ventilation in
the first hours after admission. All of the females had
hypertension in the medical history.
These results, as well as the lower use of fibrinolytic ther-
apy among eligible women than men, raise the possibility
of gender differences in AMI treatment in Bulgaria. The
lack of knowledge or sensitivity towards gender specific
symptoms and risk factors related to IHD, especially
within the outpatient setting, may be explained by a lack
of training of medical personnel in this regard. Our find-
ings regarding gender specific mortality in ACS patients
need further investigation.
LOS
Regardless of the treatment actually provided, the health
care service purchaser NHIF limits the duration of in-hos-BMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
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pital treatment in Bulgaria to eight days. The comparison
of the LOS in Stara Zagora hospitals with data from other
countries, especially from Western and Central Europe
shows that patients in Stara Zagora with ACS have shorter
median stays. The mean hospital stay with lysis is 13 ± 5
days in the PRAGUE-2 trial [28] as opposed to 9 ± 3 days
for the Stara Zagora region.
Generalisation of the study results
The survey we conducted represents the management of
AMI for 5% of the Bulgarian population. The results
obtained may be representative for most regions, with the
exception of the national capital. Currently, the health
care system of Bulgaria cannot provide sufficient PCIs,
which is the reason why fibrinolytic reperfusion and con-
servative drug therapy remain the methods of choice for
ACS treatment. Internationally, fibrinolytic therapy dem-
onstrated remarkable life-saving effects never observed
before and at the same time represented the beginning of
"millionaire medicine" [26].
Regardless of the fact that the resources allocated by the
NHIF do not cover the expenses, the fund has selected
Alteplase or Reteplase to be the only fibrinolytic drugs in
Bulgaria. Other Central European countries, which, like
Bulgaria, are reforming their health sector, continue to use
Streptokinase routinely, although they obviously have
better funding capacity [28]. In addition, Streptokinase is
still used as the treatment of first choice in low-risk
patients in the UK, Australia, New Zealand and the Neth-
erlands [26]. Therefore, revising the NHIF disease man-
agement program for STEMI and tailoring the reperfusion
strategy in a way which acknowledges the financial situa-
tion of the Bulgarian health care system should be the first
step towards improving AMI treatment performance in
Bulgaria. If the NHIF considered the possibility of Strep-
tokinase treatment, a larger number of patients could
receive fibrinolytic reperfusion therapy leading to
improved outcomes of inpatient management of STEMI.
Conclusion
In spite of the efforts of health care policy-makers to
improve the system, the results of the health sector
reforms in Bulgaria, particularly within the field of cardi-
ology, still show much room for improvement. Quality of
care of patients with AMI in Bulgaria is still far from the
evidence-based recommendations. 18 years after the
breakdown of the former socialist Semashko system, the
Bulgarian health care system is still not able to provide
state of the art health care to decrease AMI mortality. To
achieve the goal of reducing cardiovascular disease mor-
tality by introducing up-to date management of ACS, Bul-
garia will have to provide financial and human resources
which are currently neither available in the region of Stara
Zagora nor in the rest of the country.
Study limitations
Our study is limited in a number of ways. First of all, the
data were collected retrospectively from inpatient records.
In Bulgarian hospitals, methodological standards for the
contents of inpatient records concerning medical history,
smoking habits, body-mass index, and indications for
treatment have not been introduced. Thus, we were not
able to encompass all important patient characteristics in
our study.
Of particular concern is the issue of the discharge diagno-
sis. Despite the fact that the NHIF has implemented diag-
nostic criteria for AMI (STEMI and NSTEMI) and the
medical staff do their best to fulfil them in order to receive
the reimbursement fee for patients' treatment, there is a
tendency of "up-coding" in some cases.
The exact pain-to-door time was only available for 74% of
the study population. The relationship between pre-hos-
pital time delay and socio-demographic factors is
included in the study, but the item needs further investi-
gation in a larger population.
Similarly, the age and sex differences in treatment at dis-
charge and in mortality need to be investigated in larger
populations.
Notwithstanding the limitations mentioned above, our
work depicts the inpatient care for patients with ACS in a
representative region of Bulgaria. In addition, the study
brings forward some of the obstacles for improving qual-
ity of health care for AMI which is the most important bur-
den of the health care system and the entire Bulgarian
society.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MGI conceived and designed the study and drafted the
manuscript. KK performed data analysis and revised the
manuscript critically for important intellectual content.
MG contributed to conception and design of the study
and revised the manuscript critically for important intel-
lectual content. All authors read and approved the final
manuscript.
Acknowledgements
We want to thank Alexander Rosen, Werner Arend, and Irene and Geof-
frey Heller for their linguistic support.
References
1. National Statistical Institute, Ministry of Health – National Center of
Health Informatics: Public health statistics annual, Bulgaria
2000.  National Center of Health Informatics: Sofia: Statistical Print;
2001. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2009, 9:15 http://www.biomedcentral.com/1472-6963/9/15
Page 10 of 10
(page number not for citation purposes)
2. National Statistical Institute, Ministry of Health – National Center of
Health Informatics: Public health statistics annual, Bulgaria
2004.  National Center of Health Informatics: Sofia: Statistical Print;
2005. 
3. Armstrong P: New advances in the management of acute cor-
onary syndromes: Fibrinolytic therapy for acute ST-segment
elevation myocardial infarction.  CMAJ 2001, 165:791-797.
4. Brodie B, Stuckey T, Muncy DB, Hansen C, Wall T, Pulsipher M,
Gupta N: Importance of time-to-reperfusion in patients with
acute myocardial infarction with and without shock treated
with primary percutaneous coronary intervention.  Am Heart
J 2003, 145:708-715.
5. Gibson M: Has my patient achieved adequate myocardial
reperfusion?  Circulation 2003, 108:504-507.
6. Giugliano RP, Braunwald E: Selecting the Best Reperfusion
Strategy in ST-Elevation Myocardial Infarction.  Circulation
2003, 108:2828-2830.
7. Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV, Brindis RG, Smith
SC, Harrington RA, Fintel D, Fraulo ES, Califf RM, Gibler WB, Ohman
EM, Peterson ED: Recent trends in the care of patients with
non-ST-segment elevation acute coronary syndromes.  Arch
Intern Med 2006, 166:2027-2034.
8. Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV, Foody JM,
Boden WE, Smith SC, Gibler WB, Ohman EM, Peterson ED: Evolu-
tion in cardiovascular care for elderly patients with non-ST-
segment elevation acute coronary syndromes.  J Am Coll Cardiol
2005, 46:1479-87.
9. National Statistical Institute:  [http://www.nsi.bg/SocialActivities_e/
Health.htm].
10. National Statistical Institute:  [http://www.nsi.bg/Population/
PopByRPL04.htm].
11. National Framework Contract 2003:  [http://www.nhif.bg/bg/
default.phtml?w=991&h=738].
12. Tasseva T: Optimizing of therapeutic care in the case of acute
myocardial infarction – dissertation work for awarding of the
scientific degree of Doctor of Medicine.  Specialized scientific
council of social medicine at the Higher Attestation Commission.
Sofia; 2005. 
13. Björklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson
K, Werf F Van De, Wallentin L, the Swedish ASSENT-2 and RISK-HIA
Investigators: Outcome of ST-elevation myocardial infarction
treated with thrombolysis in the unselected population is
vastly different from samples of eligible patients in a large-
scale clinical tria.  Am Heart J 2004, 148:566-573.
14. Luthi J-C, McClellan WM, Flanders WD, Pitts SR, Burnand B: Varia-
tions in the quality of care of patients with acute myocardial
infarction among Swiss university hospitals.  Int J Qual Health
Care 2005, 17:229-234.
15. Goldberg RJ, Yarzebski J, Lessard D, Gore JM: Decade-long trends
and factors associated with time to hospital presentation in
patients with acute myocardial infarction: the Worcester
Heart Attack Study.  Arch Intern Med 2000, 160:3217-3223.
16. Sari I, Acar Z, Özer O, Erer B, Tekbas ¸ E, Üçer E, Genç A, Davutoğlu
V, Aksoy M: Factors associated with prolonged prehospital
delay in patients with acute myocardial infarction.  Türk Kardi-
yol Dern Ars ¸ 2008, 36:156-162.
17. Ganova-Iolovska M, Kalinov K, Geraedts M: Satisfaction of inpa-
tients with acute coronary syndrome in Bulgaria.  Health and
Quality of Life Outcomes 2008, 6:50.
18. Tang EW, Wong C-K, Herbison P: Global registry of acute coro-
nary events (GRACE) hospital discharge risk score accu-
rately predicts long-term mortality post acute coronary
syndrome.  Am Heart J 2007, 153:29-35.
19. Quality of Care and Outcomes Research in CVD and Stroke Working
Groups: Measuring and improving Quality of Care.  Circulation
2000, 101:1483-1493.
20. Jencks SF, Cuerdon T, Burwen DR, Fleming B, Houck PM, Kussmaul
AK, Nilasena DS, Ordin DL, Arday DR: Beneficiaries: a profile at
state and national levels quality of medical care delivered to
Medicare.  JAMA 2000, 284:1670-1676.
21. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E,
Fioretti PM, Simoons ML, Battler A: A prospective survey of the
characteristics, treatment and outcomes of patients with
acute coronary syndromes in Europe and the Mediterranean
basin.  European Heart Journal 2002, 23:1190-1201.
22. Rathore SS, Berger AK, Weinfurt KP, Feinleib M, Oetgen WJ, Gersh
BJ, Schulman KA: Race, sex, poverty, and the medical treat-
ment of acute myocardial infarction in the elderly.  Circulation
2000, 102:642-648.
23. Antmann EM, Anbe DT, Armstromg PW, Bates ER, Green LA, Hand
M, Hochman JS, Krumholz HM, Kusher FG, Lamas GA, Mullany CJ,
Ornato JP, Pearle DL, Sloan MA, Smith SC, Alper JS, Anderson JL,
Faxon DP, Fuster V, Gibbson RJ, Gregoratos G, Halperin JL, Hiratzka
LF, Hunt SA, Jacobs AK: ACC/AHA guidelines for the manage-
ment of patients with ST-elevation myocardial infarction.
Circulation 2004, 110:e82-e293.
24. The GUSTO Investigators: An international randomized trial
comparing four thrombolytic strategies for acute myocar-
dial infarction.  NEJM 1993, 329:673-682.
25. Van de Werf FJ, Antman EM, Simoons ML: Managing ST-elevation
myocardial infarction.  European Heart Journal 2002, 4(Suppl
E):E15-E23.
26. Ribichini F, Ferrero V, Wijns W: Reperfusion treatment of ST-
elevation acute myocardial infarction.  Progress in Cardiovascular
Diseases 2004, 47:131-157.
27. Carrabba N, Santoro GM, Balzi D, Barchielli A, Marchionni N, Fabiani
P, Landini C, Scarti L, Santoro G, Valente S, Verdiani V, Buiatti E: In-
hospital management and outcome in women with acute
myocardial infarction.  Am J Cardio 2004, 94:1118-1123.
28. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Ascher-
mann M, Branny M, Stasek J, Formanek P: Long distance transport
for primary angioplasty vs. immediate thrombolysis in acute
myocardial infarction. Final results of the randomized
national multicentre trial – PRAGUE-2.  European Heart Journal
2003, 24:94-104.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/9/15/prepub